Skip to main content
Clinical Trials/NCT03263468
NCT03263468
Unknown
Not Applicable

Revascularization StrategIes for ST Elevation Myocardial Infarction Trial

Unity Health Toronto0 sites3,520 target enrollmentSeptember 1, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
ST Elevation Myocardial Infarction
Sponsor
Unity Health Toronto
Enrollment
3520
Primary Endpoint
Major adverse clinical events
Last Updated
8 years ago

Overview

Brief Summary

This study is being conducted in patients with a major heart attack caused by a blocked artery undergoing Percutaneous Coronary Intervention (PCI) to open up the blockage. Up to 50% of people with an heart attack are found to have one or more additional narrowings that did not cause the heart attack. At present the best way to manage these additional blockages is not known. Many cardiologist recommend opening these blockages at at a later time after the heart attack. The present study is examining if PCI of all blockages at the same time as the PCI for the artery that caused the major heart attack (SS-PCI) will reduce the amount of heart damage compared to performing PCI of additional blockages 2-45 days later (IRA-PCI). Clinical follow up will be completed at 3, 12 and 24 months to determine heart function and monitor adverse events.

Registry
clinicaltrials.gov
Start Date
September 1, 2017
End Date
December 31, 2021
Last Updated
8 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • ST elevation myocardial infarction evidenced by new ST elevation at the J point in at least 2 contiguous leads of ≥ 2 mm (0.2mV) in men or ≥ 1.5mm (0.15mV) in women in leads V2-V3 and/or ≥ 1mm (0.1mV) in other contiguous chest leads or limb leads.
  • MVD as evidenced by \> one significant (\>70% by visual assessment or FFR \< 0.80 for 50-70% stenosis) stenosis in the non-IRA \>2mm in diameter.
  • Successful IRA-PCI with \<30% residual angiographic stenosis and TIMI III flow
  • Written informed consent

Exclusion Criteria

  • Age ≤ 18 years
  • Prior coronary artery bypass graft (CABG) surgery
  • Administration of thrombolytic therapy.
  • Hemodynamic instability as evidenced by SBP\<90 mmHg, Killip class ≥3, and/or need for inotropes/vasopressors.
  • Known renal insufficiency (estimated GFR \< 30 ml/min/1.73m2)
  • Non-IRA stenosis is a chronic total occlusion (CTO)
  • Plan by treating physician to treat non-IRA stenosis with coronary artery bypass surgery

Outcomes

Primary Outcomes

Major adverse clinical events

Time Frame: 90 days

Composite of all-cause mortality, myocardial infarction, heart failure and unplanned revascularization

Secondary Outcomes

  • Major bleeding(90 days)
  • Stroke(90 days)
  • Contrast nephropathy(90 days)
  • Major vascular complication(90 days)
  • EQ-5D quality of life assessment(90 days)
  • Myocardial infarction(90 days)
  • All cause mortality(90 days)
  • Unplanned revascularization(90 days)
  • Incremental Cost-Effectiveness Ratio (ICER)(90 days)
  • Heart failure(90 days)

Similar Trials